D-0154-2018 Class II Terminated

Recalled by ALLERGAN — Madison, NJ

FDA drug recall D-0154-2018 was initiated by ALLERGAN on Dec 4, 2017 and is designated Class II. Reason for recall: Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile. The recall status is terminated (terminated Jun 20, 2019). Affected quantity: 12,699 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 17, 2018
Initiation Date
Dec 4, 2017
Termination Date
Jun 20, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,699 bottles

Product description

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

Reason for recall

Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Distribution pattern

U.S.A. nationwide

Code information

Lot #: 160741A, Exp 02/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0154-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0154-2018. Report a data issue: hello@regdatalab.com.